Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H27N3O2 |
| Molecular Weight | 389.4901 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C(=O)C[C@H]2N(C(=O)C3=CC4=C(CCC4)C=C23)C5=CC=CC=C5
InChI
InChIKey=MBGOHVUPIPFVMM-JOCHJYFZSA-N
InChI=1S/C24H27N3O2/c1-25-10-12-26(13-11-25)23(28)16-22-20-14-17-6-5-7-18(17)15-21(20)24(29)27(22)19-8-3-2-4-9-19/h2-4,8-9,14-15,22H,5-7,10-13,16H2,1H3/t22-/m1/s1
| Molecular Formula | C24H27N3O2 |
| Molecular Weight | 389.4901 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:36:41 GMT 2023
by
admin
on
Sat Dec 16 11:36:41 GMT 2023
|
| Record UNII |
MD92F5Z441
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1013427-48-9
Created by
admin on Sat Dec 16 11:36:41 GMT 2023 , Edited by admin on Sat Dec 16 11:36:41 GMT 2023
|
PRIMARY | |||
|
DTXSID201029752
Created by
admin on Sat Dec 16 11:36:41 GMT 2023 , Edited by admin on Sat Dec 16 11:36:41 GMT 2023
|
PRIMARY | |||
|
17755150
Created by
admin on Sat Dec 16 11:36:41 GMT 2023 , Edited by admin on Sat Dec 16 11:36:41 GMT 2023
|
PRIMARY | |||
|
JM-1232
Created by
admin on Sat Dec 16 11:36:41 GMT 2023 , Edited by admin on Sat Dec 16 11:36:41 GMT 2023
|
PRIMARY | JM-1232 is a sedative and hypnotic drug being researched as a potential anesthetic. It has similar effects to sedative-hypnotic benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine hypnotic. It was developed by a team at Maruishi Pharmaceutica. A human study explored the sedation caused by infusions at a range of doses, finding a fair hemodynamic safety profile. | ||
|
MD92F5Z441
Created by
admin on Sat Dec 16 11:36:41 GMT 2023 , Edited by admin on Sat Dec 16 11:36:41 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Maruishi Pharmaceutical; Class: Benzodiazepine, Indole; Mechanism of Action: GABA A receptor modulator; Highest Development Phase: Phase I for Anaesthesia, Anxiety disorders; Most Recent Events: 19 Nov 2008 Phase-I clinical trials in Anaesthesia in Japan (unspecified route), 19 Nov 2008 Phase-I clinical trials in Anxiety disorders in Japan (unspecified route)
|
||
|
ACTIVE MOIETY |
Eight rats were used in each dose of each group. Intrathecal JM 1232(-) increased the tail flick latency and decreased the number of flinches in both phases 1 and 2 of the formalin test. These changes were antagonized by intrathecal flumazenil but not by naloxone. Intraperitoneal JM 1232 (-) had no effects on the tail flick latency, but decreased the number of flinches in both phases 1 and 2 of the formalin test. The latter was antagonized by intraperitoneal flumazenil and naloxone with bigger effects of flumazenil. Intraperitoneal JM 1232(-) 3000 microg induced reversible motor disturbance. In conclusion, intrathecal JM 1232(-) exerts antinociceptive effects on acute thermal and inflammatory stimuli through benzodiazepine-GABA(A) receptors in the spinal cord. Intraperitoneal JM 1232(-) was antinociceptive only against inflammatory stimulus and this is mediated mainly by benzodiazepine-GABA(A) receptors, but partially by micro-opioid receptors in the brain.
|
